Australian-run cancer care provider GenesisCare will roll out AI-powered adaptive radiotherapy software across more than 40 Australian radiation oncology centres from July after a pilot found the technology could help clinicians identify patients whose treatment plans need to change as their anatomy changes during treatment.
GenesisCare will deploy Sydney startup SeeTreat Medical’s ART.1 software to support personalised assessment of eligible patients receiving radiation therapy. The software automatically analyses changes occurring over a course of treatment and alerts clinicians when a patient may benefit from a revised treatment plan, helping prioritise cases that require clinical review.
SeeTreat CEO and Founder, Dr Trang Nguyen said, “GenesisCare is a truly patient-centric and innovative organisation with passionate doctors and clinical staff constantly striving to deliver the best care possible. Working with the GenesisCare team is a pleasure and we’re proud to be collaborating with the group.”
SeeTreat, founded in Sydney in 2023 by radiation oncologist Dr Trang Nguyen, Antonia Dalton and Professor Paul Keall, said its ART.1 software is already registered for clinical use in Australia, Europe and the UK, with US regulatory clearance announced earlier this year.
Adaptive radiotherapy allows clinicians to modify treatment plans when tumours shrink or patients’ anatomy changes during treatment, reducing unnecessary radiation exposure to healthy tissue. However, reviewing every patient’s imaging manually is labour intensive, limiting widespread adoption.
GenesisCare Chief Medical Officer Dr Marcus Dreosti, said “whilst radiation treatment is proven to be a safe and highly effective cancer treatment, unwanted toxicities and side effects can occur due to changes in a patient’s anatomy over the course of treatment. Optimising treatment post commencement, called ‘adaptive radiotherapy’, is labour intensive and complex. We’re excited that through this collaboration with SeeTreat, we now have the opportunity to make adaptive radiotherapy more accessible for patients across our Australian network.”
The rollout follows a multidisciplinary evaluation involving 64 patients with head and neck, breast and prostate cancers treated across GenesisCare’s mixed-vendor linear accelerator fleet. According to the company, the study demonstrated the software’s potential to standardise adaptive radiotherapy workflows while providing clinicians with decision support on which patients should be considered for replanning.
Add Comment